(Neo-)adjuvant treatments in colorectal cancer

Annals of Oncology

Volumn 16, Issue SUPPL. 2, 2005, Pages

  Arnold, D ^a   Schmoll, H J ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DRUG METABOLITE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; MONOCLONAL ANTIBODY; OXALIPLATIN; RADIOSENSITIZING AGENT; RALTITREXED; SEMUSTINE; UFT;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG SUBSTITUTION; DRUG TRANSFORMATION; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; LYMPH NODE METASTASIS; META ANALYSIS; MONOTHERAPY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; RISK BENEFIT ANALYSIS; SEPSIS; SYSTEMATIC REVIEW; TREATMENT FAILURE; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS;

EID: 21344438905     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi729     Document Type: Review

References (81)

1. Jemal A, Murray T, Samuels A et al. Cancer statistics. CA Cancer J Clin 2003; 53: 5-26.
2. Buyse M, Zeleniuch-Jaquotte A, Chalmers T et al. Adjuvant therapy of colorectal cancer-why we still don't know. JAMA 1988; 259: 3571-3578.
3. Laurie JA, Moertel CG, Fleming TR et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989; 7: 1447-1456.
4. Moertel CG, Fleming TR, MacDonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-358.
5. NIH consensus conference. Adjuvant therapy for patients with colorectal cancer. JAMA 1990; 264: 1444-1450.
6. Wolmark N, Rockette H, Fisher B et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993; 11: 1879-1887.
7. International Multicenter Pooled Analysis of Colon Cancer Trials (IMPACT). Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939-945.
8. O'Connell MJ, Laurie JA, Kahn M et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16: 295-300.
9. Haller DG, Catalano PJ, MacDonald JS et al. Fluorouracil, leucovorin and levamisole adjuvant therapy for colon cancer: 5 years final report of INT-0089. Proc Am Soc Clin Oncol 1998; 17: (Abstr 982).
10. O'Connell MJ, Mailliard JA, Kahn MJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246-250.
11. Zaniboni A. Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival. J Clin Oncol 1997; 15: 2432-2441.
12. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
13. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
14. Grothey A, Deschler B, Kroening et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/ FA +oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002; 21: 129a (Abstr 512).
15. Saltz L, Cox JV, Blanke C. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
16. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
17. Köhne CH, van Cutsem E, Wils JA et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC GI Group study 40986. Proc Am Soc Clin Oncol 2003; 22: 254 (Abstr 1018).
18. André T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
19. de Gramont A, Boni C, Navarro M et al. Oxaliplatin/5FU/LV in stage II and III colon cancer: Updated results (as of January 04) for efficacy and neurotoxicity of the MOSAIC trial. Ann Oncol 2004; 15 (Suppl 3): iii73.
20. Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). Proc Am Soc Clin Oncol 2004; 23: 245s (Abstr 3500).
21. Rothenberg ML, Kuhn JG, Schaf LJ et al. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Ann Oncol 2001; 12: 1631-1641.
22. Cassidy J, Scheithauer W, McKendrick J et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study). Proc Am Soc Clin Oncol 2004; 22: 3509.
23. Wolmark N, Wieand S, Lembersky B et al. A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: results of NSABP protocol C-06. Proc Am Soc Clin Oncol 2004; 23: 247s (Abstr 3508).
24. Scheithauer W, McKendrick J, Begbie S et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003; 14: 1735-1743.
25. Sargent DJ, Wieand S, Benedetti J et al. Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials. Proc Am Soc Clin Oncol 2004; 23: 245s (Abstr 3502).
26. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicenter Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) investigators. J Clin Oncol 1999; 17: 1356-1363.
27. Marsoni S, on behalf of the IMPACT investigators. Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. Semin Oncol 2001; 28 (Suppl 1): 14-19.
28. Moertel CG, Fleming TR, Macdonald JS et al. Intergroup study of 5FU plus levamisole as adjuvant treatment for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995; 13: 2936-2943.
29. Figueredo A, Charette ML, Maroun J. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004; 22: 3395-3407.
30. Gill S, Loprinzi CL, Sargent DJ. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22: 1797-1806.
31. Mamounas E, Wieand S, Wolmark N et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17: 1349-1355.
32. Gray RG, Barnwell J, Hills R et al. QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. Proc Am Soc Clin Oncol 2004; 23: 245s (Abstr 3501).
33. Hickish T, Boni C, Navarro M et al. FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): Subpopulation data from the MOSAIC trial. Proc Am Soc Clin Oncol 2004; 23: 274s (Abstr 3619).
34. Jen J, Kim H, Piantadosi S et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994; 331: 213-221.
35. Lenz HJ, Danenberg KD, Leichman CG et al. p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 1998; 1227-1234.
36. Gryfe R, Kim H, Hsieh ET et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342: 69-77.
37. Watanabe T, Wu TT, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344: 1196-1206.
38. Halling KC, French AJ, McDonnell SK et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999; 91: 1295-1303.
39. Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985; 312: 1465-1472.
40. Krook JE, Moertel CG, Gunderson LL et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324: 709-715.
41. O'Connell MJ, Martenson JA, Wieand HS et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therpy after curative surgery. N Engl J Med 1994; 331: 502-507.
42. Lee JH, Lee JH, Ahn JH et al. Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report. J Clin Oncol 2002; 20: 1751-1758.
43. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997; 336: 980-987.
44. Camma C, Giunta M, Fiorica F et al. Preoperative radiotherapy for resectable rectal cancer: a metaanalysis. JAMA 2000; 284: 1008-1015.
45. Kapiteijn E, Marijnen CAM, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for respectable rectal cancer. N Engl J Med 2001; 345: 638-646.
46. François Y, Nemoz CJ, Baulieux J et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999; 17: 2396-2402.
47. Dahlberg M, Glimelius B, Graf W et al. Preoperative irradiation affects functional results after surgery for rectal cancer. Dis Colon Rectum 1998; 41: 543-551.
48. Frykholm GJ, Pahlman L, Glimelius B. Combined chemo- and radiotherapy vs. radiotherapy alone in the treatment of primary, nonresectable adenocarcinoma of the rectum. Int J Radiat Oncol Biol Phys 2001; 50: 427-434.
49. Bosset JF, Calais G, Mineur L et al. Does the addition of chemotherapy (CT) to preoperative radiotherapy (preopRT) increase the pathological response in patients with resected rectal cancer: Report of the 22921 EORTC phase III trial. Proc Am Soc Clin Oncol 2004; 23: 246s (Abstr 3504).
50. Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004; 72: 15-24.
51. Sauer R, Becker H, Hohenberger W et al. Preoperative versus post-operative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740.
52. Gastrointestinal Tumor Study Group. Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol 1992; 10: 549-557.
53. Tepper JE, O'Connell M, Niedzwiecki D et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control-final report of Intergroup 0114. J Clin Oncol 2002; 20: 1744-1750.
54. Schüller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291-297.
55. Kim JS, Kim JS, Cho MJ et al. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2002; 54: 403-408.
56. Dunst J, Reese T, Sutter T et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 2002; 20: 3983-3991.
57. De Paoli A, Innocente R, Buonadonna A et al. Neoadjuvant therapy of rectal cancer new treatment perspectives. Tumori 2004; 90: 373-378.
58. Dupuis O, Vié B, Lledo G et al. Capecitabine (X) chemoradiation (CRT) in the preoperative treatment of patients (pts) with rectal adenocarcinomas: A phase II GERCOR trial. Proc Am Soc Clin Oncol 2004; 23: 254s (Abstr 3538).
59. Wong SJ, Sadasiwan S, Erickson B et al. A phase II trial of pre-operative capecitabine and concurrent radiation for locally advanced rectal cancer. Proc Am Soc Clin Oncol 2004; 23: 311s (Abstr 3771).
60. Cividalli A, Ceciarelli F, Livdi E et al. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys 2002; 52: 1092-1098.
61. Gérard JP, Chapet O Nemoz C et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol 2003; 21: 1110-1124.
62. Carraro S, Roca E, Cartelli C et al. Radiochemotherapy with daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study. Int J Radiat Oncol Biol Phys 2002; 54: 397-402.
63. Alonso V, Salud A, Escudero P et al. Preoperative chemoradiation with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma. Proc Am Soc Clin Oncol 2004; 23: 271s (Abstr 3607).
64. Gambacorta MA, Valentini V, Coco C et al. Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: Phase I and II studies. Int J Radiat Oncol Biol Phys 2004; 60: 139-148.
65. Casado E, De Castro J, Castelo B et al. Phase II study of neoadjuvant treatment of rectal cancer with oxaliplatin, raltitrexed and radiotherapy. Proc Am Soc Clin Oncol 2004; 23: 305s (Abstr 3746).
66. Aschele M, Vitali ML, Binda GA et al. A phase I study of uracil/tegafur (UFT) and oral leucovorin (LV) + weekly oxaliplatin (OXA) and preoperative radiotherapy (RT) in locally advanced rectal cancer (LARC). Proc Am Soc Clin Oncol 2004; 23: 279s (Abstr 3637).
67. Rödel C, Grabenbauer GG, Papadopoulos T et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21: 3098-3104.
68. Glynne-Jones R, Sebag-Montefiore D, McDonald A et al. Preliminary phase II SOCRATES study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC). Proc Am Soc Clin Oncol 2004; 23: 263s (Abstr 3575).
69. Duck LR, Sempoux C, Honhon H et al. A phase II study of preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with locally advanced rectal adenocarcinoma. Proc Am Soc Clin Oncol 2004; 23: 258s (Abstr 3552).
70. Tucci E, Algeri R, Giulianotti PC et al. Preoperative capecitabine, oxaliplatin and high-dose pelvic conformal radiotherapy in locally advanced rectal cancer (LARC). Proc Am Soc Clin Oncol 2004; 23: 281s (Abstr 3646).
71. Mehra VK, Cho C, Ford JM et al. Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys 2003; 55: 132-137.
72. Mitchell EP, Anne PR, Fry R et al. Chemoradiation with CPT-11, 5FU in neoadjuvant treatment of locally advanced or recurrent adenocarcinoma of the rectum: A phase I/II study update. Proc Am Soc Clin Oncol 2003; 22: 262 (Abstr 1052).
73. Navarro M, Dotor E, Rivera F et al. A phase II study of irinotecan (CPT-11) and 5-Fluorouracil (5-FU) concomitantly with preoperative radiotherapy (RT) in patients (pts) with locally advanced resectable rectal cancer. Proc Am Soc Clin Oncol 2003; 22: 308 (Abstr 1235).
74. Levine EL, Gollins S, Susnerwala S et al. Phase II study of radiotherapy plus concurrent irinotecan (CPT-11) and infusional 5-fluorouracil (5FU) in the treatment of T3-T4 locally advanced inoperable rectal cancer. Proc Am Soc Clin Oncol 2004; 23: 273s (Abstr 3612).
75. Klautke G, Foitzik TK, Ludwig K et al. Intensified neoadjuvant chemoradiotherapy (CRT) with capecitabine and irinotecan in patients with locally advanced rectal cancer (LARC): A phase I/II study. Proc Am Soc Clin Oncol 2004; 23: 292s (Abstr 3693).
76. Hofheinz RD, von Gerstenberg-Helldorf B et al. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 2005; 23: 1350-1357.
77. Queißer W, Hartung G, Kopp-Schneider A et al. Adjuvant radiochemotherapy with 5-fluorouracil and leucovorin in stage II and III rectal cancer. Onkologie 2000; 23: 334-339.
78. Fountzilas G, Zisiadis A, Dafni U et al. Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1999; 10: 671-676.
79. Fisher B, Wolmark N, Rockette H et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: Results from NSABP Protocol R-01. J Natl Cancer Inst 1988; 80: 21-29.
80. Wolmark N, Wieand HS, Hyams DM et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 2000; 92: 388-396.
81. Willett CG, Chung D, Sahani D et al. Phase I study of neoadjuvant bevacizumab, 5-fluorouracil, and radiation therapy followed by surgery for patients with primary rectal cancer. Proc Am Soc Clin Oncol 2004; 23: 3589.